Seeking Alpha

Roche in-licenses tech platform from Amunix Pharma for non-cancer therapies

|About: Roche Holding AG (RHHBY)|By: , SA News Editor

Privately held Amunix Pharmaceuticals has out-licensed its T cell engager technology platform, XTEN, to Roche (OTCQX:RHHBY) aimed at discovering and developing non-oncology therapeutics against undisclosed targets.

Under the terms of the agreement, Roche will pay Amunix $40M upfront, up to $1.5B in milestones and royalties on net sales.

Try Seeking Alpha PREMIUM for unlimited analysis on RHHBY